Alere Toxicology Plc.

What Alere Toxicology Plc. does

Alere Toxicology Plc. operates the Abbott Toxicology division following Abbott's 2017 acquisition of Alere. The division provides drug and alcohol testing solutions spanning rapid point-of-collection screening devices (including the iCup urine drug test cup), high-complexity laboratory testing services for urine and oral fluid specimens, and online result reporting systems (DATALINK, WEBORDERS). It serves workplace screening programs, government agencies (federal, state, local, law enforcement, military), clinical toxicology providers, and physician office laboratories, with a stated 30+ years of toxicology experience and multiple dedicated laboratory facilities worldwide.

The business operates three distinct revenue streams: fee-for-service laboratory drug testing (transactional), hardware and reagent sales for rapid point-of-collection screening, and recurring subscription access to online result-reporting platforms. Its go-to-market is enterprise field sales with dedicated account management, supported by self-serve portals for existing customers. Customer education is delivered through the Learning Xchange platform, segmented by criminal justice and workplace/clinical audiences. The product portfolio is rooted in established immunoassay and confirmatory laboratory chemistry rather than AI-driven analytics, and the division differentiates on global lab infrastructure, regulatory certifications, and the Abbott brand rather than technology novelty.

Alere Toxicology Plc. is the UK-registered entity (Abingdon, England) within a broader Abbott Toxicology division that operates globally. Abbott itself is a publicly traded diversified healthcare company (NYSE: ABT, founded 1888); toxicology segment revenue is not separately disclosed. The division's competitive positioning rests on installed enterprise relationships, laboratory scale, and integration with Abbott's broader diagnostics and medical device portfolio rather than independent standalone financial metrics.

Name

Alere Toxicology Plc.

Legal name

Abbott

Website

https://aleretoxicology.co.uk

Company type

Public

Founded year

1888

Operating status

Operating

Headcount range

51–100 employees

Short description

Alere Toxicology Plc. operates the Abbott Toxicology division, providing rapid point-of-collection drug screening devices, laboratory urine and oral fluid testing services, and online result reporting for workplace, government, clinical, and physician office customers worldwide.

Ownership category

akta.pro rank

Product category

Drug and Alcohol Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels) (HLAHAOAG)

akta.pro secondary industries

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Drug & Alcohol Testing Coordination (BPACALAE)

Keywords

• Drug testing services
• Toxicology diagnostics
• Workplace drug screening
• Laboratory drug analysis
• Rapid screening devices

Headquarters

HQ city

Not specified

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Drug Testing Services: Fee-for-service laboratory testing including urine and oral fluid analysis with result reporting
2. Rapid Screening Products: Sale of rapid screening devices and reagents for point-of-collection drug testing
3. Online Result Reporting Services: Subscription-based access to online result reporting platforms for organizations managing drug testing programs

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Alere Toxicology provides drug and alcohol testing solutions for workplace, government, and clinical customers. Offerings include rapid point-of-collection screening devices such as the iCup™ urine drug test cup and reagents, high-complexity laboratory drug testing services for urine and oral fluid specimens, and secure online result reporting platforms (DATALINK, WEBORDERS). The company operates multiple dedicated toxicology laboratories worldwide with 30+ years of testing experience.

Product overview

Alere Toxicology Plc. (now part of Abbott) offers a comprehensive drug and alcohol testing portfolio comprising rapid point-of-collection screening devices (including the iCup™ urine test cup), laboratory testing services (urine and oral fluid), online result reporting systems, and reagents. The product portfolio spans from managed solutions and onsite point-of-collection testing to high-complexity laboratory services with 30+ years of experience, supported by multiple laboratory facilities dedicated to toxicology worldwide. Key offerings include rapid screening devices for instant results, comprehensive lab-based testing, and digital result management platforms.

Differentiator

Problem solved

Functional benefit

Brands

• iCup: Rapid drug test cup - most widely used rapid drug test cup product
• DATALINK
• Learning Xchange

Products and services

• iCup Urine Test Drug Screening Device

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Quest Diagnostics: One of the largest clinical laboratory networks in the U.S., offering extensive employer drug testing services alongside broad diagnostic testing. Competes directly with Abbott Toxicology for workplace and government screening contracts at greater scale.
• Thermo Fisher Scientific: Large diversified life sciences and diagnostics company supplying analytical instruments, reagents, and clinical testing services relevant to toxicology laboratories. Operates adjacent to Abbott Toxicology in lab testing infrastructure.
• Laboratory Corporation of America (Labcorp): Major clinical laboratory operator providing workplace drug testing, forensic toxicology, and clinical diagnostics. Overlaps significantly with Abbott Toxicology's lab services business and competes for large enterprise and government accounts.
• Bio-Rad Laboratories: Global diagnostics and life science research company with clinical diagnostics and laboratory quality control products relevant to clinical toxicology workflows. Overlaps with Abbott Toxicology in diagnostic testing infrastructure.

Direct peers

• Omega Laboratories: Specialized toxicology laboratory providing hair, urine, and oral fluid drug testing for legal, employment, and clinical applications. Closely comparable to Abbott Toxicology's lab services and rapid screening offerings.
• Psychemedics Corporation: Specialized drug testing company focused on hair-based drug screening for employers and law enforcement. A direct competitor in the workplace and government drug testing segment, distinguished by its proprietary hair testing methodology.
• American Bio Medica Corporation: Developer and manufacturer of rapid drug test kits for workplace, government, and clinical markets. Directly competes with Abbott Toxicology's point-of-collection drug screening products.
• Clinical Reference Laboratory (CRL): Private clinical reference laboratory offering workplace drug testing, clinical diagnostics, and specialized toxicology services. Competes directly with Abbott Toxicology for employer and clinical toxicology customers.
• Premier Biotech: Manufacturer of rapid urine drug screening devices and reagents distributed to workplaces, courts, and clinical sites. Directly competes with iCup and the rapid screening product line.

Emerging players

• Confirm BioSciences: Provider of drug and alcohol testing products and laboratory services for employers, healthcare providers, and individuals. Competes in the same point-of-care and lab testing markets with a smaller, more focused portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alere-toxicology-plc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alere Toxicology Plc.